Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Active, not recruiting Not applicable

The Effects of Neuro-Athletic Training on Performance Parameters and Injury Risk in Taekwondo Athletes

NCT07702136 · tracked via the Priya Life Science Turkey tracker
Phase
Not applicable
Started
2025-10-01
Last updated
2026-07-14

Condition(s) studied

Athletes

Investigational drug(s) / intervention(s)

Neuro-athletic trainingtraining program

Neuro-athletic training: Neuroathletic training is a treatment approach that, in addition to regular training, provides athletes with more sensory input to the central nervous system and trains them neurologically.

training program: It is a regular training program prepared for athletes specific to the sport field.

Study summary

Our study is a randomized controlled trial. The aim of the study is to investigate the effects of neuro-athletic training on balance, agility, jump performance parameters, and injury risk in Taekwondo athletes.

Hypotheses H0: Neuro-athletic training has no effects on balance, agility, jump performance parameters, and injury risk in Taekwondo athletes.

H1: Neuro-athletic training has effects on balance, agility, jump performance parameters, and injury risk in Taekwondo athletes.

Sample

A total of 26 participants will be included in the study. Randomization will be used to divide them into two groups:

Experimental group: 13 participants Control group: 13 participants Inclusion Criteria

* Regular participation in Taekwondo training for at least 2 years
* No musculoskeletal injury within the last 6 months
* Participation in Taekwondo training at least 2 days per week during the past 2 years
* Athletes with an anterior reach distance asymmetry of 4 cm or more after Y-Balance Test (YBT)
* Voluntary participation in the study Exclusion criteria for participants;
* Having had hip/pelvis, knee, or ankle surgery in the past year,
* Having a neurological disease,
* Using any medication that could affect balance, having a vestibular system disorder,
* Having a diagnosis of attention deficit.

Eligibility

Sex
ALL
Min age
8 Years
Max age
—
Healthy volunteers
Accepted
Inclusion criteria: * Attending taekwondo training regularly for at least 2 years * Not having had any muscle or skeletal injuries in the last 6 months * Training in taekwondo at least 2 days a week in the past 2 years * Athletes with anterior reach distance asymmetry of 4 cm or more after YDT * Being willing to participate in the study Exclusion criteria: * Having had hip/pelvis, knee, or ankle surgery in the past year * Having a neurological disease * Using any medication that could affect balance, having a vestibular system disorder * Being diagnosed with attention deficit

Primary outcome measure(s)

  • Risk of injury — start and 8 weeks
    The risk of injury will be assessed with the Y Balance Test. There are no specific upper or lower limits in the Y Balance Test; however, clinically accepted threshold values exist. The most critical threshold is an asymmetry greater than 4 cm between legs in the anterior direction and a composite score of less than 94%, which significantly increases the risk of injury.

Trial sites (1)

FacilityCityRegionStatus
Pamukkale Üniversitesi Denizli Turkey (Türkiye)
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07702136 on ClinicalTrials.gov ↗ ← All trials in Turkey